BANK VONTOBEL/CALL/ELI LILLY & CO/620/0.1/20.09.24 | Delayed Deutsche Boerse AG 09:24:20 21/06/2024 BST | ||
| 25.82 EUR | +3.36% |
|
| Current month | +30.17% | ||
| 1 month | +50.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 25.82 | +3.36% |
| 20/06/24 | 24.98 | -5.74% |
| 19/06/24 | 26.5 | +2.67% |
| 18/06/24 | 25.81 | -0.96% |
| 17/06/24 | 26.06 | +3.17% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 09:24 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM3L3W |
| ISIN | DE000VM3L3W7 |
| Date issued | 06/10/2023 |
| Strike | 620 $ |
| Maturity | 20/09/2024 (92 Days) |
| Parity | 10 : 1 |
| Emission price | 4.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.94 € |
|---|---|
| Lowest since issue | 4.61 € |
| Spread | 0.22 € |
| Spread % | 0.85% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
- Stock Market
- Warrants
- Warrant
